- Home
- AXG vs JANX Comparison
AXG vs JANX Comparison
Compare AXG & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXG | JANX |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.2M | 890.8M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AXG | JANX |
|---|---|---|
| Price | $3.61 | $13.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $57.36 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 01-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,656,000.00 | ★ $10,000,000.00 |
| Revenue This Year | $28.53 | N/A |
| Revenue Next Year | $54.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 216.49 | N/A |
| 52 Week Low | $1.16 | $12.12 |
| 52 Week High | $5.09 | $44.83 |
Technical Indicators
Market Signals| Indicator | AXG | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 36.48 |
| Support Level | $2.69 | $12.12 |
| Resistance Level | $3.70 | $14.16 |
| Average True Range (ATR) | 0.36 | 0.75 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 48.99 | 17.66 |
Price Performance
Historical ComparisonAbout AXG Solowin Holdings Class A Ordinary Share
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.